Precision Biosciences (DTIL) Cash from Financing Activities (2018 - 2026)

Precision Biosciences (DTIL) has reported Cash from Financing Activities for 9 consecutive years, with $745000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Financing Activities fell 93.03% year-over-year to $745000.0; the TTM figure through Mar 2026 stood at $85.2 million (up 305.0% YoY), while the FY2025 annual figure was $95.2 million, up 88.63% from the prior year.
• Cash from Financing Activities eased to $745000.0 in Q1 2026 per DTIL's latest filing, from $77.5 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $92.9 million in Q2 2022 and bottomed at -$180000.0 in Q3 2022.
• Historically, Cash from Financing Activities has averaged $15.4 million across 5 years, with a median of $2.5 million in 2022.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities plunged 101.51% — and 2024, when it surged 11079.41%.
• Precision Biosciences' Cash from Financing Activities stood at -$180000.0 in 2022, then jumped by 1671.11% to $2.8 million in 2023, then jumped by 109.34% to $5.9 million in 2024, then soared by 1209.39% to $77.5 million in 2025, then plunged by 99.04% to $745000.0 in 2026.
• Business Quant data shows DTIL's Cash from Financing Activities at $745000.0 in Q1 2026, $77.5 million in Q4 2025, and $1.7 million in Q3 2025.